Communiqués Monopar Therapeutics Inc.

Actions

MNPR

US61023L1089

Temps Différé Nasdaq Autres places de cotation 19:08:34 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,734 ^USD	+3,38%		-0,94%	+115,76%

09/07	Monopar Therapeutics Inc. annonce le recrutement d'un premier patient dans le cadre du premier essai de phase 1 sur l'homme pour son nouveau produit radiopharmaceutique MNPR-101-Zr	CI
24/05	Monopar Therapeutics nomme Karthik Radhakrishnan au poste de directeur financier	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr	09/07	GL
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24	25/06	GL
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24	25/06	AQ
Monopar and NorthStar Amend & Extend Collaboration	11/06	GL
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting	10/06	GL
Monopar Announces CFO Succession	24/05	GL
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline	09/05	GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	18/04	GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	18/04	AQ
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	16/04	GL
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	10/04	GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments	28/03	GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments	28/03	AQ
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program	05/03	GL
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial	27/02	GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	22/02	GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	22/02	AQ
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers	20/02	GL
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments	09/11	GL
"Unleashing a Medical Revolution: Transformative Breakthroughs in Diagnosis and Treatment" VTAK, ALDX, MNPR, INBS, SIEN	08/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Monopar Therapeutics Inc.

Actions

MNPR

US61023L1089

Communiqués

Filtres